Sight Sciences Inc (SGHT) - News Archive

Sight Sciences Announces Medicare Fee Schedule for TearCare Procedure, Enhancing Access to Interventional Dry Eye Treatment MENLO PARK, Calif., Oct. 17, 2025 Sight Sciences, Inc. (Nasdaq: SGHT), a pioneering eyecare tec...

Cost-Effective Innovations in Ocular Health: Budget Impact Analysis of Sight Sciences’ TearCare System for Meibomian Gland DiseaseThe field of ophthalmology is on the cusp of transformation with the innovative introduct...

In a notable shift aimed at reinvigorating its strategic direction, Sight Sciences Inc. has recently appointed MK Raheja as Executive Vice President of Research and Development, and Brenton Taylor as Executive Vice Pres...

Dry eye disease (DED) remains a significant public health concern, impacting the quality of life of individuals globally. Recent advancements in treatment options, particularly investigator-initiated clinical trials inv...

Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance MENLO PARK, Calif., Aug. 01, 2024 Sight Sciences, Inc. (Nasdaq: SGHT), a pioneering eyecare technology company,...

Sight Sciences Inc (NASDAQ: SGHT) has garnered significant attention recently, with a flurry of insider activity and market performance that has left investors intrigued. This article delves into the key events surround...

Sight Sciences Announces Promising Results from The ROMEO Study: OMNI Shows Effective Reductions in Pressure and Medication Usage Across All Stages of GlaucomaIn an exciting development for glaucoma patients, Sight Scie...

Precision medicine has emerged as a game-changer in the field of healthcare, providing tailored treatments for patients based on their genetic profiles. Predicine, a leader in precision medicine and biomarker solutions,...

Sight Sciences, a leading medical technology company, has recently published a groundbreaking study demonstrating the efficacy of their OMNI Surgical System in treating glaucoma. The study, which evaluated over 100,000...

In a remarkable breakthrough for the field of ophthalmology, Sight Sciences showcased the remarkable results of their GEMINI Trial and the cross-over phase of the SAHARA RCT at the prestigious 2024 American Society of C...

Refinancing Replaces Prior Senior Credit Facility: A Step Towards Financial StabilityIn the ever-evolving landscape of finance, companies often need to adapt and find innovative solutions to manage their debt and mainta...

TearCare Eyelid Procedures Show Promising Results in Treating Dry Eye Disease: SAHARA Clinical Trial Reveals Significant ImprovementsIn a recent press release, Sight Sciences, a leading medical technology company, annou...

Sight Sciences, a leading medical device company, has recently made an exciting announcement regarding the acceptance for publication of GEMINI 2, a three-year, prospective, multicenter trial evaluating the OMNI Surgica...